The predominant variants are the one from South Africa and the B117 from England. For those two variants, the vaccine response seems adequate with both vaccines, from Pfizer and from Moderna. The South African strain shows some resistance to the antibodies that the vaccines generate and we know that the AstraZeneca vaccine is less effective for that variant. However, it is not sufficient to impair the effectiveness of vaccination. All the vaccines are effective in protecting people against the severe infections that require hospitalization or cause death.
That is encouraging for now, but it does not mean that other variants will not emerge and possibly turn out to be completely resistant to current vaccines. That should encourage us, therefore, to be even more careful and to take advantage of local and national opportunities to quickly begin producing new vaccines or boosters, because we may well be needing them next year.